Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.34 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrazine SCHEMBL4472691 | 0.97 | NOTUM (0.41) | NOTUMMAPK1PDE10ATRPV3IDO1 | |
| SCHEMBL16660961 | 0.76 | TRPV3 (0.40) | NOTUMMAPK1PDE10ATRPV3 | |
| SCHEMBL628734 | 0.74 | PDE10A (0.39) | NOTUMMAPK1PDE10ATRPV3KDM5A | |
| Water SCHEMBL4472702 | 0.73 | MAPK1 (0.38) | NOTUMMAPK1PDE10ATRPV3IDO1 | |
| SCHEMBL4934121 | 0.72 | ALOX5AP (0.36) | NOTUMMAPK1 | |
| SCHEMBL25190562 | 0.71 | TRPV3 (0.42) | NOTUMMAPK1PDE10ATRPV3IDO1 | |
| SCHEMBL15167135 | 0.71 | TRPV3 (0.40) | NOTUMMAPK1PDE10ATRPV3HTT | |
| SCHEMBL629954 | 0.69 | TRPV3 (0.42) | MAPK1PDE10ATRPV3IDO1MAPT | |
| SCHEMBL3540420 | 0.69 | IDO1 (0.40) | MAPK1PDE10ATRPV3IDO1NPC1 | |
| SCHEMBL4482079 | 0.68 | MAPK1 (0.44) | MAPK1PDE10ATRPV3NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586594-B2 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBVIE INC. (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2117526-B1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBOTT LAB (US) | 2013-04-03 | — | — | EP | disclosed |
| US-20120238581-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBVIE INC. | 2012-09-20 | — | — | US | disclosed |
| US-8202878-B2 | Type 2 diabetes, obesity, elevated plasma triglycerides, metabolic syndrome, non-alcoholic steatohepatitis, and non-alcoholic fatty liver disease;Trans [4-(4-{3-[2-(1-adamantyl)-2-hydroxyethoxy]-1H-pyrazol-5-yl}phenyl)cyclohexyl]acetic acid | ABBOTT LABORATORIES (US) | 2012-06-19 | — | — | US | disclosed |
| US-20080182861-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBVIE INC. | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238581-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | DGAT1, DGAT2, LCAT | NOTUM 242/4885MAPK1 222/4885PDE10A 1074/4885 |
| US-20080182861-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | DGAT1, DGAT2, LCAT | NOTUM 243/4885MAPK1 227/4885PDE10A 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.